Kensler, Kevin H. http://orcid.org/0000-0001-7515-7270
Regan, Meredith M.
Heng, Yujing J.
Baker, Gabrielle M.
Pyle, Michael E.
Schnitt, Stuart J.
Hazra, Aditi
Kammler, Roswitha
Thürlimann, Beat
Colleoni, Marco
Viale, Giuseppe
Brown, Myles
Tamimi, Rulla M.
Article History
Received: 6 September 2018
Accepted: 10 February 2019
First Online: 22 February 2019
Ethics approval and consent to participate
: All patients provided informed written consent and all study protocols were approved by ethics committees at each BIG 1–98 study center and by relevant health authorities.
: Not applicable.
: MMR has received research funding for IBCSG clinical trials from Novartis, Pfizer, Ipsen, Merck, Ferring, and Pierre Fabre and research funding from Novartis, Veridex, OncoGenex, Bayer, and Bristol-Myers Squibb, and serves in a consulting or advisory role for Ipsen and Bristol-Myers Squibb. MC receives an honorarium from Novartis and is a consultant for Pierre Fabre, Pfizer, OBI Pharma, Puma Biotechnology, Celldex, and AstraZeneca. MB receives sponsored research support from and has been a consultant to Novartis. MB has served on the scientific advisory board of Gtx, Inc. and currently serves on the scientific advisory board of Kronos Bio.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.